Phase II Multicenter Randomized Open-Label Trial of Denosumab with MAP Regimen in Metastatic Osteosarcoma Patients
- Trial ID
- 2024-518167-35-01
- Protocol
- AIEOP-ISG OsM+
Register record, history and transparency: CTIS.eu
Trial statistics
Diseases & Conditions
Objectives
The primary objective of this Phase II, multicentre, randomised, open-label trial is the evaluation of the effectiveness of **denosumab** in combination with standard chemotherapy in patients with metastatic osteosarcoma. This is clinically relevant as it aims to determine whether the addition of denosumab can enhance the therapeutic outcomes in this patient population, potentially leading to improved treatment protocols.
Secondary objectives include:
- Overall Survival (OS): Assessing the impact of the treatment regimen on the survival duration of patients.
- Safety and toxicity of combination treatment: Evaluating the adverse effects and tolerability of the combined treatment regimen.
- Evaluation of RANK/RANKL expression and tumor inflammatory infiltrate: Investigating these biomarkers in both the primary tumor and metastatic sites at diagnosis and post-therapy, and correlating them with treatment response.
Participants
The clinical trial involves **patients with metastatic osteosarcoma**, focusing on evaluating the effectiveness of denosumab in combination with standard chemotherapy. The study population includes both male and female participants, aged between 12 and 40 years, who have a histologically confirmed diagnosis of high-grade metastatic osteosarcoma at onset. Participants are required to have an ECOG Performance status of 2 or less, or a Lansky Score of 40% or more, indicating a relatively stable general health status. Adequate bone marrow, liver, and kidney function are necessary, with specific laboratory values outlined for inclusion. Female participants of childbearing potential must have a negative pregnancy test prior to each chemotherapy cycle, and all potentially fertile participants must agree to use effective contraception during the study. The trial does not include a vulnerable population. The sponsor has not provided information regarding the total number of participants in the study.
Plans and Procedures
The clinical trial is a **Phase II**, multicentre, randomized, open-label study designed to evaluate the effectiveness of **denosumab** in combination with standard chemotherapy in patients with metastatic **osteosarcoma**. The trial involves a comparison between a regimen of MAP (methotrexate, doxorubicin, and cisplatin) with and without the addition of denosumab. The study is expected to run until April 6, 2031, with recruitment having commenced on April 6, 2023. The primary endpoint is the 5-year Event-Free Survival (EFS), which assesses systemic recurrence in patients with no evidence of disease or progression in those who have not undergone surgery and thus have evidence of disease.
Participants will undergo a series of study visits, beginning with an inclusion (screening) visit to confirm eligibility based on criteria such as age, performance status, and adequate organ function. The trial includes follow-up visits to monitor treatment response and adverse events, with the end-of-study visit marking the conclusion of participant involvement. The expected duration of participant involvement is up to 32 weeks for those receiving MAP chemotherapy, with a shorter duration of 12 weeks for those receiving denosumab. Conditions that may lead to early termination from the study include significant adverse events, withdrawal of consent, or non-compliance with study procedures.
The trial employs a randomized design to ensure unbiased allocation of participants to treatment groups, and the open-label nature allows both participants and investigators to be aware of the treatment being administered. The study involves intravenous administration of the investigational products, with dosing regimens tailored to the specific pharmacological properties of each agent. The trial is conducted in accordance with ethical guidelines, and informed consent is obtained from all participants or their legal representatives prior to any trial-specific procedures.
Treatment
The clinical trial involves the administration of several **experimental medications** for the treatment of metastatic osteosarcoma. The first medication is **Cisplatin**, marketed as CISPLATINO Pfizer 100 mg/100 ml soluzione per infusione. This is a **solution for infusion** and is administered via **intravenous use**. The dosage is calculated based on body surface area, with a maximum daily dose of 60 mg/m² and a total maximum dose of 600 mg/m² over a treatment period of up to 32 weeks. The active substance, cisplatin, is of chemical origin and is provided by Pfizer Italia S.R.L.
The second medication is **Methotrexate**, available as Metotressato Teva 25 mg/ml soluzione iniettabile. This is a **solution for injection** and is also administered intravenously. The dosage is measured in grams per square meter, with a maximum daily dose of 12 g/m² and a total maximum dose of 120 g/m² over a 32-week period. Methotrexate is a chemical product supplied by Teva Italia S.R.L.
The third medication is **Doxorubicin Hydrochloride**, marketed as Doxorubicina Teva 2 mg/ml concentrato per soluzione per infusione. This is a **solution for infusion** administered intravenously. The dosing is based on milligrams per square meter, with a maximum daily dose of 75 mg/m² and a total maximum dose of 420 mg/m² over a 32-week treatment period. The active substance is of chemical origin and is provided by Teva Italia S.R.L.
The fourth medication is **Denosumab**, marketed as XGEVA 120 mg solution for injection. This is a **solution for injection** administered intravenously. The maximum daily dose is 120 mg, with a total maximum dose of 1680 mg over a 12-week period. Denosumab is a protein-based product supplied by Amgen Europe B.V.
In this trial, the combination of these medications is evaluated for their effectiveness in treating patients with metastatic osteosarcoma. The trial is open-label and randomized, with a focus on the potential benefits of adding denosumab to the standard chemotherapy regimen. Participant compliance is monitored throughout the study to ensure adherence to the dosing schedules and administration routes.
Efficacy
The efficacy of the treatment regimen in the clinical trial will be assessed using the primary endpoint of 5-year **Event Free Survival (EFS)**. This endpoint is defined as the time until systemic recurrence in patients with no evidence of disease or progression in patients who have not undergone surgery and therefore have evidence of disease. The trial aims to evaluate the effectiveness of denosumab in combination with standard chemotherapy in patients with metastatic osteosarcoma. The assessment of efficacy will be conducted over a period that aligns with the trial's estimated end date of April 6, 2031. The collection and analysis of data related to the primary endpoint will be performed in accordance with the trial's protocol, ensuring that the results are scientifically valid and reliable.
Inclusion and Exclusion Criteria
Inclusion Criteria
- The patient (or his/her legal representative) must be able to read and understand the informed consent form and must provide his/her written informed consent prior to any trial-specific procedure
- Histologically confirmed diagnosis of high-grade metastatic osteosarcoma at onset
- Age ≥ 12 years (or having reached skeletal maturity) and ≤ 40 years
- ECOG Performance status ≤ 2 or Lansky/Karnofsky Score ≥ 40%.
- Adequate bone marrow function defined as follows: White blood cells >3.0 x 109/L, Absolute neutrophil count >1.5 x 109/L, Platelets >100 x 109/L, Haemoglobin > 9 g/d
- Adequate liver and kidney function defined as follows: Total bilirubin < 2 Upper Limit of Normality (LSN), AST (SGOT) <3.0 x LSN, ALT (SGPT) <3.0 x LSN, GGT <2.5 x LSN, Blood calcium ≥ 8.0 mg/dl and ≤ 11.5 mg/dl, Creatinine: Creatininemia < 1.5 mg/mL or creatinine clearance of 60 mL/min/1.73m2 for patients with creatinine levels above the normal limit
- Left Ventricular Ejection Fraction > 50%
- female patients of childbearing age must have a negative pregnancy test in the 7 days prior to the start of each chemotherapy cycle. Any post-menopausal women must have been amenorrhoeic for at least 12 months to be considered potentially infertile. Potentially fertile male and female patients must agree to use an effective method of contraception during the study
Exclusion Criteria
- Medical contraindications to the use of the drugs in the protocol
- Known history of HIV infection
- Active or chronic hepatitis B or C requiring treatment with antiviral drugs
- Evidence of any serious or unstable medical, psychological, or social illness or condition that may compromise the patient's safety and/or compliance with participation in the trial or evaluation of results
- Known hypersensitivity to the trial drug or its class or to excipients present in the formulation of the trial drugs
- Known hypersensitivity to calcium or vitamin D
- Any situation that might jeopardise treatment compliance
- Subjects with known Central Nervous System metastases
- Previous treatment with denosumab or other bisphosphonates
- Hypocalcaemia not controlled with oral calcium supplementation
- Previous history or evidence of osteonecrosis of the jaw
- Dental contraindications to the use of denosumab
- Cardiovascular disease with NYHA status >2. History of myocardial infarction less than 6 months prior to the start of treatment. Patients with unstable angina and severe life-threatening arrhythmia are excluded
- Medical history of arterial thrombotic or embolic events such as cerebrovascular infarctions (including transient ischaemic attacks - TIA) or pulmonary embolisms in the 6 months prior to the start of trial treatment
- Pregnancy and/or breastfeeding at the time of diagnosis
Trial Status by Country
| Country | Status | Start of Recruitment | Planned Patients |
|---|---|---|---|
Italy | Recruiting | 06 Apr 2023 | 88 |
Sites & Investigators
Investigational Products
Details about the medicinal products being studied in this clinical trial.
| Product Name | Role in Trial | Formulation | Administration | Max Daily Dose | Treatment Duration | EU MP Number |
|---|---|---|---|---|---|---|
Metotressato Teva 25 mg/ml soluzione iniettabile | Test | SOLUZIONE INIETTABILE | INTRAVENOUS USE | 12 | 32 | PRD734748 |
Doxorubicina Teva 2 mg/ml concentrato per soluzione per infusione | Test | CONCENTRATO PER SOLUZIONE PER INFUSIONE | INTRAVENOUS USE | 75 | 32 | PRD474662 |
XGEVA 120 mg solution for injection | Test | SOLUTION FOR INJECTION | INTRAVENOUS USE | 120 | 12 | PRD4647077 |
CISPLATINO Pfizer 100 mg/100 ml soluzione per infusione | Test | SOLUZIONE PER INFUSIONE | INTRAVENOUS USE | 60 | 32 | PRD499844 |

